Synaptogenix (TAOX) Competitors $4.53 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.62 +0.09 (+2.08%) As of 05/22/2026 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock TAOX vs. PLYX, VTVT, PYXS, THAR, and EQShould you buy Synaptogenix stock or one of its competitors? MarketBeat compares Synaptogenix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Synaptogenix include Polaryx Therapeutics (PLYX), vTv Therapeutics (VTVT), Pyxis Oncology (PYXS), Tharimmune (THAR), and Equillium (EQ). These companies are all part of the "pharmaceutical products" industry. TAOX vs. PLYXTAOX vs. VTVTTAOX vs. PYXSTAOX vs. THARTAOX vs. EQHow does Synaptogenix compare to Polaryx Therapeutics?Polaryx Therapeutics (NASDAQ:PLYX) and Synaptogenix (NASDAQ:TAOX) are both small-cap manufacturing companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability. Does the media refer more to PLYX or TAOX? In the previous week, Polaryx Therapeutics' average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score. Company Overall Sentiment Polaryx Therapeutics Neutral Synaptogenix Neutral Do insiders and institutionals believe in PLYX or TAOX? 10.3% of Synaptogenix shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is PLYX or TAOX more profitable? Polaryx Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets Polaryx TherapeuticsN/A N/A N/A Synaptogenix N/A -163.40%-133.47% Which has better valuation and earnings, PLYX or TAOX? Polaryx Therapeutics has higher earnings, but lower revenue than Synaptogenix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolaryx TherapeuticsN/AN/AN/AN/AN/ASynaptogenix$300K112.80-$28.74M-$13.28N/A Do analysts rate PLYX or TAOX? Polaryx Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 177.78%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Polaryx Therapeutics is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polaryx Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryPolaryx Therapeutics beats Synaptogenix on 5 of the 8 factors compared between the two stocks.How does Synaptogenix compare to vTv Therapeutics?Synaptogenix (NASDAQ:TAOX) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability. Do insiders & institutionals believe in TAOX or VTVT? 10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate TAOX or VTVT? vTv Therapeutics has a consensus price target of $53.00, suggesting a potential upside of 54.07%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe vTv Therapeutics is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00vTv Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Is TAOX or VTVT more profitable? vTv Therapeutics' return on equity of 3.96% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -163.40% -133.47% vTv Therapeutics N/A 3.96%2.86% Which has higher earnings & valuation, TAOX or VTVT? vTv Therapeutics has higher revenue and earnings than Synaptogenix. vTv Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenix$300K112.80-$28.74M-$13.28N/AvTv Therapeutics$1.02M132.88-$26.97M-$0.93N/A Which has more risk and volatility, TAOX or VTVT? Synaptogenix has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Does the media refer more to TAOX or VTVT? In the previous week, vTv Therapeutics had 8 more articles in the media than Synaptogenix. MarketBeat recorded 8 mentions for vTv Therapeutics and 0 mentions for Synaptogenix. vTv Therapeutics' average media sentiment score of 0.25 beat Synaptogenix's score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Synaptogenix Neutral vTv Therapeutics Neutral SummaryvTv Therapeutics beats Synaptogenix on 14 of the 16 factors compared between the two stocks.How does Synaptogenix compare to Pyxis Oncology?Synaptogenix (NASDAQ:TAOX) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability. Do institutionals and insiders believe in TAOX or PYXS? 10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, TAOX or PYXS? Synaptogenix has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Is TAOX or PYXS more profitable? Pyxis Oncology's return on equity of -135.60% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -163.40% -133.47% Pyxis Oncology N/A -135.60%-85.00% Which has preferable earnings and valuation, TAOX or PYXS? Synaptogenix has higher earnings, but lower revenue than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenix$300K112.80-$28.74M-$13.28N/APyxis Oncology$13.86M8.96-$79.62M-$1.31N/A Do analysts rate TAOX or PYXS? Pyxis Oncology has a consensus target price of $6.83, suggesting a potential upside of 248.64%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Does the media refer more to TAOX or PYXS? In the previous week, Pyxis Oncology had 12 more articles in the media than Synaptogenix. MarketBeat recorded 12 mentions for Pyxis Oncology and 0 mentions for Synaptogenix. Pyxis Oncology's average media sentiment score of 0.48 beat Synaptogenix's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the news media. Company Overall Sentiment Synaptogenix Neutral Pyxis Oncology Neutral SummaryPyxis Oncology beats Synaptogenix on 11 of the 15 factors compared between the two stocks.How does Synaptogenix compare to Tharimmune?Synaptogenix (NASDAQ:TAOX) and Tharimmune (NASDAQ:THAR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation. Do analysts prefer TAOX or THAR? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is TAOX or THAR more profitable? Synaptogenix's return on equity of -163.40% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -163.40% -133.47% Tharimmune N/A -588.45%-264.41% Which has more volatility and risk, TAOX or THAR? Synaptogenix has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Which has better valuation & earnings, TAOX or THAR? Tharimmune has lower revenue, but higher earnings than Synaptogenix. Tharimmune is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenix$300K112.80-$28.74M-$13.28N/ATharimmuneN/AN/A-$12.20M-$3.99N/A Does the media prefer TAOX or THAR? In the previous week, Tharimmune had 1 more articles in the media than Synaptogenix. MarketBeat recorded 1 mentions for Tharimmune and 0 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.00 equaled Tharimmune'saverage media sentiment score. Company Overall Sentiment Synaptogenix Neutral Tharimmune Neutral Do insiders and institutionals believe in TAOX or THAR? 10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummarySynaptogenix beats Tharimmune on 6 of the 10 factors compared between the two stocks.How does Synaptogenix compare to Equillium?Synaptogenix (NASDAQ:TAOX) and Equillium (NASDAQ:EQ) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations. Do insiders & institutionals hold more shares of TAOX or EQ? 10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 17.8% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is TAOX or EQ more profitable? Equillium's return on equity of -61.43% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -163.40% -133.47% Equillium N/A -61.43%-53.72% Which has better valuation & earnings, TAOX or EQ? Equillium has higher revenue and earnings than Synaptogenix. Equillium is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenix$300K112.80-$28.74M-$13.28N/AEquillium$41.10M3.48-$22.40M-$0.32N/A Which has more risk & volatility, TAOX or EQ? Synaptogenix has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Equillium has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Does the media refer more to TAOX or EQ? In the previous week, Equillium had 1 more articles in the media than Synaptogenix. MarketBeat recorded 1 mentions for Equillium and 0 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.00 equaled Equillium'saverage media sentiment score. Company Overall Sentiment Synaptogenix Neutral Equillium Neutral Do analysts prefer TAOX or EQ? Equillium has a consensus price target of $7.67, suggesting a potential upside of 239.23%. Given Equillium's stronger consensus rating and higher possible upside, analysts plainly believe Equillium is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Equillium 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 SummaryEquillium beats Synaptogenix on 13 of the 15 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for TAOX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TAOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TAOX vs. The Competition ExportMetricSynaptogenixPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$33.85M$927.43M$4.26B$12.34BDividend YieldN/A4.84%5.93%5.28%P/E Ratio-0.341.4621.9025.65Price / Sales112.80119.63180.5586.28Price / CashN/A20.0755.6856.67Price / Book1.467.5934.857.14Net Income-$28.74M-$3.64M$112.32M$335.98M7 Day Performance-5.43%1.93%2.55%3.56%1 Month Performance-12.72%76.78%3.54%2.54%1 Year PerformanceN/A126.62%15.79%35.05% Synaptogenix Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TAOXSynaptogenix0.0441 of 5 stars$4.53flatN/AN/A$33.85M$300KN/A4Positive NewsGap DownPLYXPolaryx TherapeuticsN/A$3.05+14.2%$10.00+228.0%N/A$143.39MN/AN/A11VTVTvTv Therapeutics2.887 of 5 stars$35.78-6.9%$53.00+48.1%+93.7%$139.95M$1.02MN/A9Gap UpPYXSPyxis Oncology3.5858 of 5 stars$2.21-3.2%$6.83+209.6%+59.3%$139.81M$13.86MN/A60Gap DownTHARTharimmune0.0069 of 5 stars$3.62-3.5%N/A+159.3%$136.58MN/AN/A2 Related Companies and Tools Related Companies Polaryx Therapeutics Alternatives vTv Therapeutics Alternatives Pyxis Oncology Alternatives Tharimmune Alternatives Equillium Alternatives Rani Therapeutics Alternatives OnKure Therapeutics Alternatives Genelux Alternatives Alpha Cognition Alternatives Turn Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TAOX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
